Bellerophon Therapeutics (NASDAQ:BLPH) Research Coverage Started at assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) in a research note released on Saturday. The firm issued a sell rating on the biotechnology company’s stock.

Several other research firms have also commented on BLPH. Brookline Capital Acquisition dropped their price objective on shares of Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Brookline Capital Management dropped their target price on shares of Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th.

BLPH opened at $0.96 on Friday. The stock’s 50 day simple moving average is $1.72 and its 200 day simple moving average is $2.34. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $5.95. The firm has a market cap of $9.21 million, a price-to-earnings ratio of -0.51 and a beta of -0.17.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities research analysts anticipate that Bellerophon Therapeutics will post -2.31 EPS for the current fiscal year.

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 24,134 shares of the biotechnology company’s stock, valued at approximately $75,000. Millennium Management LLC owned 0.25% of Bellerophon Therapeutics at the end of the most recent quarter. 12.93% of the stock is owned by institutional investors.

About Bellerophon Therapeutics (Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Stories

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.